Spiderwort secures $13.2M USD in Series A Financing to Accelerate Clinical Trials of Revolutionary Biomaterials

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Spiderwort Inc, a biotech company specializing in the development of transformative biomaterials for repairing and regenerating tissues within the human body, recently announced securing $13.2 million USD in Series A financing. The financing was led by Horizons Ventures and supported by K5 Global, BoxOne Ventures and Break Off Capital.

The funding will advance Spiderwort’s innovations in cellulose-based tissue scaffolding to treat acute spinal cord injuries. The investment will support the transition from pre-clinical studies to the clinical trials that are critical to bringing Spiderwort’s revolutionary biomaterial to market. As the company focuses on this next phase of trials, it is committed to delivering a transformative treatment option to the medical professionals and patients who need it most.

Spiderwort Inc. is an OBIO® member and a previous CAAP®, HealthMINT™, BDSP™ and H2BB™ participant.

Arsheen Kaur
Previous

Allarta Team behind breakthrough research that aims to cure diabetes
Next

Increasing the Adoption of Canadian Innovations and Focusing on Women’s Leadership/Accroître l’adoption des innovations canadiennes et mettre à l’honneur le leadershipdes femmes